News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly Evolocumab in AMI patients undergoing coronary intervention DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe Bempedoic acid: The new kid on the block Immunotherapies in homozygous FH: Alirocumab and evinacumab ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ESC Congress 2020
The Digital Experience

29 August – 1 September

HAUSER-RCT: Evolocumab in paediatric heterozygous FH
HAUSER-RCT: Expert viewpoint; latest videos
DA-VINCI: LDL management in Europe
Evolocumab in AMI patients undergoing coronary intervention

ACC.20 with the World Congress of Cardiology

Virtual Meeting 28-30 March

Polygenic risk, LDL and SBP
Inclisiran: Data for >3,600 patients
Evinacumab: Nearly halves LDL-C in HoFH

Most viewed

How much do you have to reduce Lp(a) to achieve significant clinical benefit? DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe Lp(a): Risk factor or causal factor? A critical appraisal Immunotherapies in homozygous FH: Alirocumab and evinacumab Bempedoic acid: The new kid on the block Evolocumab in AMI patients undergoing coronary intervention No adverse effects of very low LDL cholesterol on cognition: further data from FOURIER ORION-9 Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial ORION-11

Most viewed

How much do you have to reduce Lp(a) to achieve significant clinical benefit?

Hot Topics

12th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum

Lipoprotein(a) in the spotlight

Professor Børge Nordestgaard (University of Copenhagen, Denmark) appraises the evidence

Watch the webcast

Lp(a): Findings in ODYSSEY OUTCOMES

Professor Greg Schwartz (University of Colorado School of Medicine, Aurora, USA) discusses the latest evidence

Watch the webcast

How much do you have to reduce Lp(a) to achieve significant clinical benefit?

Professor Henry Ginsberg (University of Columbia, New York, USA) draws on the data to give his view

Watch the webcast

From the Editors

Looking beyond LDL: PCSK9 inhibition and remnants

Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles

Read the report

Other related reports:
Did someone say “Beyond LDL-cholesterol”?
Read the report
New EAS Consensus Panel statement: an Opus for LDL-driven mechanisms in atherosclerosis
Read the report